Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging

Fergus V. Coakley, Irene Chen, Aliya Qayyum, Antonio C. Westphalen, Peter R. Carroll, Hedvig Hricak, Mei Hsiu Chen, John Kurhanewicz

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

OBJECTIVE: To investigate the validity of prostate-specific antigen (PSA) as a tumour marker in men with clinically localized prostate cancer who have selected watchful waiting, by determining if serial PSA level measurements are correlated with findings of malignancy or benign prostatic hyperplasia (BPH) at serial endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI). PATIENTS AND METHODS: We retrospectively identified 69 men with biopsy-proven prostate cancer being managed by watchful waiting, who underwent serial endorectal MRI/MRSI and who had contemporaneous serial PSA measurements. The mean (range) follow-up was 392 (294-571) days. A panel of three experienced readers reviewed the initial and follow-up MRI/MRSI studies, and classified findings of prostate cancer as stable or progressive. Another reader assessed BPH by calculating total gland and central gland volumes on all studies. RESULTS: At the follow-up MRI/MRSI, 51, 17 and one patient had stable, progressive, or unevaluable prostate cancer, respectively. The mean PSA velocity was significantly greater in patients with radiologically progressive disease (1.42 vs 0.42 ng/mL/year, P = 0.04). A PSA velocity of >0.75 ng/mL/year identified those with radiologically progressive disease with a true-positive fraction of 0.71 and a false-positive fraction of 0.39. PSA levels were not correlated with changes in total or central gland volumes (P > 0.05). CONCLUSIONS: In men with clinically localized prostate cancer who select watchful waiting, serial PSA levels are correlated with findings of malignancy but not BPH at serial endorectal MRI/MRSI, suggesting that PSA is a useful longitudinal tumour marker in this population.

Original languageEnglish (US)
Pages (from-to)41-45
Number of pages5
JournalBJU international
Volume99
Issue number1
DOIs
StatePublished - Jan 1 2007

Keywords

  • Biological markers
  • MRI
  • PSA
  • Prostatic hyperplasia
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging'. Together they form a unique fingerprint.

  • Cite this